The antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) is a promising treatment for EGFR inhibitor-resistant disease. "The hypothesis is that tumors that have resistance to EGFR TKIs ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...

Patritumab deruxtecan, which is currently leading the anti-HER3 pipeline, has shown efficacy in heavily pre-treated patients with EGFR-mutated NSCLC previously treated with multiple EGFR ...

Patritumab deruxtecan starts phase 3 Daiichi ... second-line therapy for EGFR-mutated advanced non-squamous NSCLC. The HER3-directed ADC will be tested in patients whose disease had progressed ...

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals ...

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 7% KEYTRUDA Sales Grew 17% to $7.4 Billion; Excluding the ...

This B cell epitope-based therapeutic vaccine may provide a novel immunotherapeutic agent against chronic HBV infection in humans. Achievement of hepatitis B virus surface antigen (HBsAg) loss is an ...